|Bid||39.26 x 400|
|Ask||39.28 x 2200|
|Day's Range||39.16 - 39.37|
|52 Week Range||37.20 - 44.58|
|PE Ratio (TTM)||44.19|
|Dividend & Yield||1.99 (5.09%)|
|1y Target Est||N/A|
The drug would be the first such treatment in Europe.
Barely four months into her tenure as chief executive of GlaxoSmithKline, Emma Walmsley is showing her determination to focus the pharmaceutical company's research and development efforts. Having said ...
The Nasdaq Biotechnology Index (NBI) was down 2.8% last week, trailing the Nasdaq and S&P 500 again, as those two broader indexes fell just 1.5% and 1.4%, respectively. Nomura Instinet's Christopher Marai ...